Business Context and Reporting Period
Spero Therapeutics, Inc. (SPRO), a Delaware corporation, filed this Form 8-K on September 10, 2020, to report the entry into a material definitive agreement for a public offering of securities. The company is an emerging growth company focused on developing novel antibiotics, specifically tebipenem HBr.
Key Financial Metrics and Capital Structure
The filing details a capital raise rather than operational financial results. Key metrics include:
- Offering Size: 4,785,000 shares of Common Stock and 3,215,000 shares of Series D Convertible Preferred Stock.
- Offering Price: $10.00 per share for both Common Stock and Series D Preferred Stock.
- Expected Net Proceeds: Approximately $74.8 million (excluding the underwriters' option).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,200,000 additional shares of Common Stock.
- Cash Runway: Management expects existing cash, net proceeds, and committed non-dilutive funding (including a BARDA contract) to fund operations into the first quarter of 2022.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the designation of 3,215,000 shares of Series D Convertible Preferred Stock, effective September 15, 2020. This new class of stock:
- Converts on a one-to-one basis into Common Stock (subject to a 9.99% beneficial ownership limitation).
- Ranks senior to Common Stock and on parity with Series A, B, and C Preferred Stock regarding liquidation preferences and dividends.
- Generally carries no voting rights except as required by law or to amend its own terms.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: The company intends to use the net proceeds to fund operating expenses and capital expenditures, specifically to support the filing and approval process of a New Drug Application (NDA) for tebipenem HBr.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include market conditions, the satisfaction of closing conditions for the offering, and uncertainties inherent in clinical development and regulatory approval. There is no assurance the offering will be completed.
Investor Verification Checklist
- Verify the final closing date of the offering (scheduled for or about September 15, 2020) and whether the underwriters' over-allotment option was exercised.
- Confirm the actual net proceeds received after deducting all underwriting discounts and offering expenses.
- Review the specific terms of the BARDA contract and other non-dilutive funding commitments cited as part of the cash runway calculation.
- Monitor the timeline for the filing and approval of the NDA for tebipenem HBr against the projected Q1 2022 funding horizon.